Adam D. Lye
Expertise in
26
conditions

Dr. Adam D. Lye

Hematology | Oncology
Norton Cancer Institute At Old Brownsboro Crossing
4955 Norton Healthcare Blvd, 
Louisville, KY 
Accepting New Patients
Offers Telehealth
19 Years of Experience
Expertise in
26
conditions
Norton Cancer Institute At Old Brownsboro Crossing
4955 Norton Healthcare Blvd, 
Louisville, KY 

Overview

Adam Lye is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 19 years.

Dr. Lye is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

Dr. Lye is board certified in American Board Of Internal Medicine, Medical Oncology - 2013 and American Board Of Internal Medicine, Internal Medicine - 2010. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 5 clinical trials. Dr. Lye is currently accepting new patients.

Graduate Institution

University Of Kentucky College Of Medicine, Doctor Of Medicine, 2007

Residency

University of Kentucky College of Medicine, Internal Medicine, 2010

Specialties

Hematology
Oncology

Licenses

Internal Medicine in KY

Board Certifications

American Board Of Internal Medicine, Medical Oncology - 2013
American Board Of Internal Medicine, Internal Medicine - 2010

Fellowships

University of Kentucky College of Medicine, Hematology and Medical Oncology, 2013

Hospital Affiliations

Norton Hospitals, Inc
Norton Clark Hospital
Baptist Health Hardin

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
MHS
  • EPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Norton Cancer Institute At Old Brownsboro Crossing
4955 Norton Healthcare Blvd, Louisville, KY 40241
Other Locations
Norton Cancer Institute - Brownsboro
4955 Norton Healthcare Boulevard, Louisville, KY 40241

Additional Areas of Focus

Dr. Lye has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Immunonutrition: does it have a role in improving recovery in patients receiving a stem cell transplant?
Immunonutrition: does it have a role in improving recovery in patients receiving a stem cell transplant?
Journal: Nutrition and cancer
Published: April 24, 2012
Similar Doctors
Expertise in
52
conditions
Dr. John L. Huber
Hematology | Oncology
Expertise in
52
conditions
Dr. John L. Huber
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (5.0 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Huber is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Huber is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Chronic Lymphocytic Leukemia (CLL), Thrombocytopenia, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Expertise in
65
conditions
Dr. Donald E. Goodin
Hematology | Oncology
Expertise in
65
conditions
Dr. Donald E. Goodin
Hematology | Oncology
Referral may be required

Hardin Memorial Health Cancer Studies

521 Robinbrooke Blvd, 
Elizabethtown, KY 
 (43.7 miles away)
270-706-1535
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Donald Goodin is a Hematologist and an Oncologist practicing medicine in Elizabethtown, Kentucky. Dr. Goodin is highly rated in 65 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Lung Cancer. Dr. Goodin is currently accepting new patients.

Expertise in
58
conditions
Dr. James S. Morgan
Hematology | Oncology
Expertise in
58
conditions
Dr. James S. Morgan
Hematology | Oncology
Referral may be required

Baptist Health Lagrange Kresge Pharmacy

4003 Kresge Way Ste 500, 
Louisville, KY 
 (5.0 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Morgan is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Morgan is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, Sleeve Gastrectomy, and Bone Marrow Aspiration. Dr. Morgan is currently accepting new patients.

Frequently Asked Questions about Dr. Adam D. Lye

How do I make an appointment with Dr. Adam D. Lye?

You can book an appointment with Dr. Adam D. Lye by calling their office at 502-394-6350. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adam D. Lye a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adam D. Lye is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adam D. Lye specialize in?

While Dr. Adam D. Lye is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Adam D. Lye participate in research or clinical trials?

Yes. Dr. Adam D. Lye has published 1 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Adam D. Lye's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adam D. Lye accept my insurance?

Dr. Adam D. Lye accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 502-394-6350 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lye's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 94 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile